Community pharmacies suffer reversals in 2006

Paul, Reid
July 2007
Drug Topics;7/9/2007, Vol. 151 Issue 13, p8
Trade Publication
This article reports on the profitability of community pharmacies in 2006. The National Community Pharmacists Association said that the number of community pharmacies shrank in 2006, reversing a five-year growth trend for the industry. According to the National Community Pharmacists Association officials, the falling profits and margins were grim signs that the Medicare Part D program was having a significant and negative impact on community pharmacies. Moreover, NCPA has also vowed to fight the CMS' proposed switch to average manufacturer price for Medicaid generic drug reimbursement.


Related Articles

  • Pharmacists livid and desperate over AMP rule. Paul, Reid // Drug Topics;8/6/2007, Vol. 151 Issue 15, p18 

    The article reports on the implementation of the average manufacturer price (AMP) reimbursement rule for Medicaid generic drugs by the Centers for Medicare & Medicaid Services (CMS). The rule states that drug prices in the Medicaid program will be reimbursed at two hundred fifty percent of the...

  • Retail Rx can't afford to let its guard down. Woldt, Jeffrey // Chain Drug Review;9/14/2009, Vol. 31 Issue 15, p16 

    The article reports on the victory of retail pharmacy operators over Delaware's decision to make cuts in Medicaid reimbursement. The Medicaid fight ended when the state agreed to rescind some of the cuts it had intended to make in reimbursements for prescriptions filled under the Medicaid...

  • Waging an all-fronts battle to halt Medicaid AMP plan. Frederick, Jim // Drug Store News;12/10/2007, Vol. 29 Issue 15, p4 

    The article reports on the unity of the National Association of Chain Drug Stores and the National Community Pharmacists Association in combating the imposition of a new round of cuts in Medicaid prescription reimbursements for genetic drugs in the U.S. Under the name, Coalition for Community...

  • Medicaid generics reimbursement outlook deemed bleak. Cassell, Dana // Drug Topics;4/2/2007 Supplement, Vol. 151, p14s 

    The article discusses the effect of the Deficit Reduction Act (DRA) on retail pharmacies in United States. DRA is the attempt of the government to slow down the rate of spending growth in Medicare and Medicaid. Under the DRA provisions, the prescription reimbursement to pharmacies shifts from...

  • Judge rules against AMP.  // Drug Topics;1/14/2008, Vol. 152 Issue 1, p6 

    The article reports that Judge Royce Lamberth has granted a temporary injunction which stops the Centers for Medicare & Medicaid Services (CMS) from implementing the average manufacturer price (AMP) rule for Medicaid generic drug reimbursement in the U.S. The move was taken in response to the...

  • Chain, independent pharmacy groups angry over multisource drug definition.  // Drug Store News;5/19/2008, Vol. 30 Issue 6, p16 

    The article reports on the implication of the U.S. Centers for Medicare and Medicaid Services' (CMS) revision of the definition of generic drugs dispensed under the Medicaid program. Such change arose the anger of independent pharmacy group leaders because they believe it could hurt both...

  • NCPA Responds to Oregon Rx Reimbursement Plan.  // Chain Drug Review;12/6/2010, Vol. 32 Issue 21, p95 

    The article reports that the National Community Pharmacists Association (NCPA) was prompted to write to the U.S. Centers for Medicare & Medicaid Services (CMS) due to concerns that pharmacists may not be able to receive reimbursement levels in planned changes to the Medicaid Program of Oregon.

  • Tuning AMP noise out of Medicaid reimbursement. Frederick, Jim // Drug Store News;8/10/2009, Vol. 31 Issue 9, p33 

    The article reports on the misunderstanding between the chain and independent pharmacy leaders and lawmakers to implement the bill new Medicaid prescription reimbursement for the generic drugs in the U.S. It mentions that the implementation of the plan is based on the average manufacturer price...

  • Industry groups weigh in on Medicaid, biosimilars.  // Chain Drug Review;11/11/2013, Vol. 35 Issue 18, p3 

    The article reports that the pharmacy groups National Association of Chain Drug Stores and National Community Pharmacists Association (NCPA) have reiterated their concerns on the proposed reimbursement limits that have inaccurate benchmark for pharmacy acquisition costs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics